This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lorch, S. A.
Right arrow Articles by Barnhart, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorch, S. A.
Right arrow Articles by Barnhart, K.
Related Collections
Right arrow Premature & Newborn
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
PEDIATRICS Vol. 114 No. 2 August 2004, pp. 417-426

Cost-Effectiveness of Inhaled Nitric Oxide for the Management of Persistent Pulmonary Hypertension of the Newborn

Scott A. Lorch, MD*,{ddagger},§, Avital Cnaan, PhD* and Kurt Barnhart, MD, MSCE§,||

* Department of Pediatrics
{ddagger} Division of Neonatology and Center for Outcomes Research, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
§ Center for Clinical Epidemiology and Biostatistics
|| Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Objective. Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that has become part of the standard management for persistent pulmonary hypertension of the newborn (PPHN). This treatment modality, like many in neonatology, has not been well studied using quantitative economic techniques. The objective of this study was to evaluate the economic impact of adding iNO to the treatment protocol of PPHN for term infants from birth to the time of discharge from their initial hospitalization.

Methods. We used decision analysis modeling from a societal perspective to obtain an incremental cost-effectiveness ratio. Outcome probabilities were taken from the medical literature and a cohort of 123 infants who were treated with PPHN at The Children’s Hospital of Philadelphia between 1991 and 2002. Costs were estimated from daily resources used by these infants in 2001 dollars. Survival and quality-adjusted life years were used as effectiveness measures. One-way, threshold, and probabilistic sensitivity analyses were performed to assess the robustness of the base-case estimate.

Results. The addition of iNO to the treatment regimen of PPHN increased the cost of treating an infant by an average of $1141, primarily from an increased number of mechanical ventilation days. Use of iNO led to 3.4% more lives saved and a 6% increase in the average utility gained per infant. The incremental cost-effectiveness ratio was $33 234 per life saved and $19 022 per quality-adjusted life year gained. The model was robust to changes in outcome probabilities, cost, and utility variables. Only 3.6% of the trials using probabilistic sensitivity analysis found iNO to be more expensive with a worse outcome than conventional therapy alone, whereas 35.7% of the trials found iNO to be cheaper and more effective than conventional treatment alone.

Conclusions. iNO is cost-effective but not cost-saving in treating infants with PPHN from a societal perspective. There are critical time points during an infant’s hospitalization that could improve the efficiency and consequently the cost of care for this patient population.

Key Words: cost-effectiveness analysis • inhaled nitric oxide • persistent pulmonary hypertension • neonate • decision analysis

Abbreviations: NICU, neonatal intensive care unit • ECMO, extracorporeal membrane oxygenation • PPHN, persistent pulmonary hypertension of the newborn • iNO, inhaled nitric oxide • CHOP, Children’s Hospital of Philadelphia • CI, confidence interval • QALY, quality-adjusted life year • CV, conventional ventilation

Received for publication Jun 13, 2003; Accepted Dec 11, 2003.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
J. A. F. Zupancic, A. M. Hibbs, L. Palermo, W. E. Truog, A. Cnaan, D. M. Black, P. L. Ballard, S. R. Wadlinger, R. A. Ballard, and and the NO CLD Trial Group
Economic Evaluation of Inhaled Nitric Oxide in Preterm Infants Undergoing Mechanical Ventilation
Pediatrics, November 1, 2009; 124(5): 1325 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
R. S. Watson, G. Clermont, J. P. Kinsella, L. Kong, R. E. Arendt, G. Cutter, W. T. Linde-Zwirble, S. H. Abman, D. C. Angus, and on behalf of the Prolonged Outcomes After Nitric O
Clinical and Economic Effects of iNO in Premature Newborns With Respiratory Failure at 1 Year
Pediatrics, November 1, 2009; 124(5): 1333 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
K. L. Kamholz, C. H. Cole, J. E. Gray, and J. A. F. Zupancic
Cost-effectiveness of Early Treatment for Retinopathy of Prematurity
Pediatrics, January 1, 2009; 123(1): 262 - 269.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. Baquero, A. Soliz, F. Neira, M. E. Venegas, and A. Sola
Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study
Pediatrics, April 1, 2006; 117(4): 1077 - 1083.
[Abstract] [Full Text] [PDF]